NUGC-3 Cells

NUGC-3 is a human gastric carcinoma cell line derived from the primary tumor of an patient with poorly differentiated adenocarcinoma. This cell line serves as an important model for studying gastric cancer, a malignancy characterized by high heterogeneity and poor prognosis in advanced stages. NUGC-3 cells are widely utilized in cancer biology research, particularly in the areas of tumor progression, metastasis, and the evaluation of novel therapeutic agents targeting gastric cancer. NUGC-3 cells exhibit epithelial morphology and are adherent under standard cell culture conditions. These cells carry genetic and molecular alterations associated with gastric adenocarcinoma, including mutations in key oncogenes and tumor suppressor genes. Researchers have leveraged this cell line to investigate signaling pathways critical to tumor growth, such as the dysregulation of EGFR, HER2, and other receptor tyrosine kinase pathways, as well as the epithelial-mesenchymal transition (EMT) process, which plays a role in cancer invasion and metastasis. This cell line is also suitable for studies on chemotherapeutic resistance, as gastric cancer frequently develops resistance to standard treatments. NUGC-3 cells are employed in drug screening assays to test the efficacy of cytotoxic agents, targeted therapies, and combination treatments. Additionally, they provide a robust platform for exploring tumor-stroma interactions and the role of the tumor microenvironment in gastric cancer progression. As such, NUGC-3 remains a valuable resource for advancing gastric cancer research and therapeutic development.